References
- Sherif K, Tello W, Nugent K. Enoxaparin-associated skin necrosis in an older patient. A rare side effect. Clin Geriatrics 2012;20:44–48
- Barber AB, Burton WC, Guyer R. The heparin-induced thrombocytopenia and thrombosis syndrome. J Bone Knee Surg 1987;69:935–937
- Franchini M. Heparin-induced thrombocytopenia: An update. Thromb J 2005;3:14
- Drew PJ, Smith MJ, Milling MAP. Heparin-induced skin necrosis and low molecular weight heparins. Ann R Coll Surg Eng 1999;81:266–269
- Fontana P, Bodrner A, Gruel Y, Boehlen F, Janer V, Kaya G, Righini M. Skin necrosis is a clinical manifestation of low-molecular weight heparin-induced thrombocytopenia. Thromb Haemost 2004;91:196–197
- Bircher AJ, Harr T, Hohenstein L, Tsakiris DA. Hypersensitivity reactions to anticoagulant drugs: Diagnosis and management options. Allergy 2006;61:1432–1440
- Handschin AE, Trentz O, Kock HJ, Wanner GA. Low molecular weight heparin-induced skin necrosis-a systematic review. Langenbecks Arch Surg 2005;390:249–254
- Arnold J, Cohen H. Heparin-induced skin necrosis. Br J Haematol 2000;111:992
- Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M; American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic therapy and prevention of thrombosis. Chest 2012;141:495–530
- Warkentin TE, Pai M, Sheppard JL, Schulman S, Spyropoulos AC, Eikelboom JW. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: A 30-month, 16-patient case series. Thromb Haemost 2011; 9:2389–2396
- Anonymous. Fondaparinux (Arixtra), a new anticoagulant. Med Lett Drugs Ther 2002;44:43–44
- Warkentin TE, Cook RJ, Marder VJ, Sheppard JA, Moore JC, Eriksson BI, Greinacher A, Kelton JG. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005;106:3791–3796